From GlobeNewswire: 2025-03-18 07:00:00

Korro Bio, Inc. completes dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency. Interim readout expected in second half of 2025. U.S. FDA grants Orphan Drug Designation to KRRO-110. Company executes 3-2-1 strategy through 2027 to establish three clinical-stage development programs. Strong balance sheet with $163.1 million in cash, cash equivalents, and marketable securities. Cash expected to fund operations through second half of 2026. (Word count: 50)

Korro Bio reports full-year 2024 financial results and progress on key objectives. Initiates Phase 1/2a REWRITE clinical study of KRRO-110 for AATD. Collaboration with Novo Nordisk announced. Pipeline advanced with multiple product candidates. Company strengthens leadership team with key additions. Interim readout of REWRITE study expected in second half of 2025. (Word count: 50)

REWRITE study evaluates safety and tolerability of KRRO-110 in up to 64 participants, including healthy adults and AATD patients with PiZZ genotype. Interim data expected in second half of 2025, completion in 2026. KRRO-110 is first RNA editing oligonucleotide product candidate from Korro’s OPERA platform. Potential to treat liver and lung disease. (Word count: 50)

Korro Bio’s financial results for 2024 show $163.1 million in cash, cash equivalents, and marketable securities. Collaboration revenue of $2.3 million earned in 2024. Research and development expenses of $63.6 million, general and administrative expenses of $30.5 million. Net loss of $83.6 million. Working capital of $116.572 million. Total assets of $226.240 million. (Word count: 50)

Korro Bio is a clinical-stage biopharmaceutical company focused on developing genetic medicines based on RNA editing for rare and prevalent diseases. Pipeline includes KRRO-110 for AATD. Korro’s RNA editing platform allows for precise single base edits. Company expects to bring medicines to patients using proprietary platform, delivery modalities, and regulatory pathways. (Word count: 50)



Read more at GlobeNewswire:: Korro Reports Full Year 2024 Financial Results and Provides